(Brussels, Belgium) - - - Kidney Disease: Improving Global Outcomes (KDIGO) has announced a major Controversies Conference on the subject of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The conference will be held in Madrid, Spain from October 24-27. More than 70 globally recognized experts in the field will meet to determine what is known about CKD-MBD, what can be done with what is known, and what we still need to learn about this topic.
KDIGO has a long tradition of organizing such Controversies Conferences. Twelve have been held to date. These conferences are a part of KDIGO’s overall mission of improving outcomes for patients with kidney disease. Development and dissemination of evidence-based clinical practice guidelines is the core mission of KDIGO that drives all its activities. KDIGO last did a guideline on CKD-MBD in 2009. One of the remits of this conference will be a recommendation as to whether or not there is sufficient new evidence available to warrant an update of that guideline.
The forthcoming CKD-MBD Controversies Conference will be co-chaired by Mary Leonard, MD of the University of Pennsylvania and Markus Ketteler, MD from the Coburg Clinic, Germany. CKD-MBD is an important co-morbidity of chronic kidney disease. From early on in the disease through to end-stage kidney failure, patients develop abnormalities of bone architecture, arterial calcification, fractures and mineral imbalances. These complications can be ameliorated by appropriate treatment, especially when intervention is started early.
KDIGO makes preliminary Scope of Work documents available for public comment prior to final planning of any Controversies Conference. Anyone wishing to comment on the CKD-MBD Scope of Work should go to www.kdigo.org/home/conferences/ckd-mbd-2013 to read the document and submit comments. Deadline for receiving comments is August 15, 2013.
KDIGO co-chair, David Wheeler of University College, London said, “KDIGO Controversies Conferences have helped the global nephrology community to recognize the level of our current knowledge (or lack of it) whilst our guidelines are driving changes to practice that are likely to lead to improvements in the care of our patients.
“In fact,” he added, “The very term CKD-MBD originated from a KDIGO Controversies Conference in 2005. We took a collection of interrelated conditions previously referred to by many different terms and structured these into a disorder. This helped kidney doctors everywhere to communicate more effectively.”
Millions of kidney patients have some degree of CKD-MBD. Their symptoms increase as kidney disease becomes more advanced. A large number of medications are available around the world to treat MBD, but not all are readily available or affordable in developing countries. As a global organization, KDIGO’s focus first is on the science of MBD and its treatment rather than on circumstances in any given country.
KDIGO co-chair Bertram Kasiske of the University of Minnesota said, “One of KDIGO’s primary tasks is to implement its scientific findings in practical strategies for every country. This implementation function is so important because clinicians need to know what the significance of a problem is before they can search what is available in their country.
“Mineral and Bone Disorder is a major factor in the lives of millions of people with kidney disease. This conference seeks to explore what has happened since the last KDIGO guideline and what treatments and medicines are available. KDIGO’s implementation network, along with that of the International Society of Nephrology, will bring this message to physicians around the world.”
KDIGO is the only global developer of evidence-based clinical practice guidelines in kidney disease. It is a self-governed Belgian foundation in the public interest led by elected volunteers and funded by donations from interested companies and individuals. Its mission is to improve global outcomes for everyone with kidney disease.
For further information please contact KDIGO Communications at email@example.com.
# # #